Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

March 19, 2025 updated by: Dr. Falk Pharma GmbH

An Open-label Study of Patients with Primary Sclerosing Cholangitis (PSC) Treated with Norucholic Acid Tablets

Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

  1. Signed informed consent.
  2. Males or females ≥ 18 years.
  3. Patient has previously been diagnosed with PSC, has participated in the previous NUC 5/PSC trial and has completed the DBE phase with Visit 22, or has prematurely terminated the DBE phase before this trial has been started, or has prematurely terminated the DBE phase after this trial has been started, under the condition that the premature termination was due to lack of efficacy*. (*Lack of efficacy as defined in the NUC-5/PSC trial.)

Exclusion Criteria:

  1. History or presence of chronic alcoholic consumption (daily consumption > 30 g in men, > 20 g in women).
  2. Patients who discontinued study participation in NUC-5/PSC due to an AE possibly caused by the study drug.
  3. Liver Cirrhosis or any cirrhosis-related symptoms which in the opinion of the investigator may affect the patient's safety.
  4. History of liver transplantation or patient listed for transplantation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: norucholic acid 1500 mg/day
3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1500 mg
500 mg norucholic acid film-coated tablets; 3 tablets/day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Occurrence of treatment emergent adverse events
Time Frame: 72 weeks from enrollment to end of treatment
72 weeks from enrollment to end of treatment
Occurrence of serious treatment emergent adverse events
Time Frame: 72 weeks from enrollment to end of treatment
72 weeks from enrollment to end of treatment
Occurrence of severe treatment emergent adverse events
Time Frame: 72 weeks from enrollment to end of treatment
72 weeks from enrollment to end of treatment
Occurrence of adverse drug reactions
Time Frame: 72 weeks from enrollment to end of treatment
72 weeks from enrollment to end of treatment
Occurrence of unexpected treatment emergent adverse events
Time Frame: 72 weeks from enrollment to end of treatment
72 weeks from enrollment to end of treatment
Occurrence of treatment emergent adverse events leading to study withdrawal
Time Frame: 72 weeks from enrollment to end of treatment
72 weeks from enrollment to end of treatment
Occurrence of adverse events leading to death
Time Frame: 72 weeks from enrollment to end of treatment
72 weeks from enrollment to end of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michael Trauner, MD, Medical University of Vienna, dept. of Internal Medicine III

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2025

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

March 14, 2025

First Submitted That Met QC Criteria

March 19, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 19, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • NUT-022/PSC
  • 2024-514292-18-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

It is not decided which data will be made available. A time frame cannot be indicated yet.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe